Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, announced Dyno-bn8, a novel adeno-associated virus ...
The inaugural Genetic Agency Technology Conference (GATC) gathered a group of researchers and entrepreneurs to discuss the vision for AI-based genetic medicine.
Dyno’s AI-designed capsids improved therapeutic gene delivery to eye, muscle and CNS compared to commonly used AAV capsids, showcasing improved delivery efficiency, target-organ specificity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback